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Abstract
Introduction: The present study was designed to determine the possibility of acetylbritannilactone (ABL) derivative
5-(5-(ethylperoxy)pentan-2-yl)-6-methyl-3-methylene-2-oxo-2,3,3a,4,7,7a-hexahydrobenzofuran-4-yl 2-(6-
methoxynaphthalen-2-yl)propanoate (ABL-N) as a novel therapeutic agent in human breast cancers.
Methods: We investigated the effects of ABL-N on the induction of apoptosis in human breast cancer cells and
further examined the underlying mechanisms. Moreover, tumor growth inhibition of ABL-N was done in xenograft
models.
Results: ABL-N induced the activation of caspase-3 in estrogen receptor (ER)-negative cell lines MDA-MB-231 and
MDA-MB-468, as evidenced by the cleavage of endogenous substrate Poly (ADP-ribose) polymerase (PARP).
Pretreatment of cells with pan-caspase inhibitor z-VAD-fmk or caspase-3-specific inhibitor z-DEVD-fmk inhibited
ABL-N-induced apoptosis. ABL-N treatment also resulted in an increase in the expression of pro-apoptotic members
(Bax and Bad) with a concomitant decrease in Bcl-2. Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38
mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific
inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis. However, the
p38-specific inhibitor SB203580 had no effect upon these processes. Moreover, neither of the caspase inhibitors
prevented ABL-N-induced JNK activation, indicating that JNK is upstream of caspases in ABL-N-initiated apoptosis.
Additionally, in a nude mice xenograft experiment, ABL-N significantly inhibited the tumor growth of MDA-MB-231
cells.
Conclusions: ABL-N induces apoptosis in breast cancer cells through the activation of caspases and JNK signaling
pathways. Moreover, ABL-N treatment causes a significant inhibition of tumor growth in vivo. Therefore, it is
thought that ABL-N might be a potential drug for use in breast cancer prevention and intervention.
Introduction
Breast cancer is one of the most common cancers among
women in both developed and underdeveloped countries.
It is the malignancy with the highest incidence and death
rate for women [1,2]. However, the efficacy of the present
drugs is very limited, and it is urgent to find the antican-
cer compounds that can target multiple points in the
apoptotic cascade to achieve synergistic actions. Chinese
herbs have obtained considerable attention for the pre-
vention and treatment of certain cancer types in clinical
studies [3-6]. In many cases, the extracts obtained from
the plants are not highly effective and require chemical
modification for improved potency and toxicity profile
[7-9]. Thus, studies of naturally plant-based agents could
supply new strategies for the management of cancer and
related diseases [7,10,11].
Recently, several phytochemicals that have been used
in clinical cancer chemotherapy were derived from
herbs and plants, such as paclitaxel [5,12], etoposide
[13], camptothecin [4] and vinca alkaloids [14]. Acetyl-
britannilactone (ABL) is a sesquiterpene lactone abun-
dant in Inula britannica L, which is used to treat
bronchitis and inflammation. In the previous work, it is
demonstrated that ABL inhibits the expression of
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cer properties [15-19]. In the course of our continuing
search for cytotoxic ABL analogues, we synthesized the
compound 5-(5-(ethylperoxy)pentan-2-yl)-6-methyl-3-
methylene-2-oxo-2,3,3a,4,7,7a-hexahydrobenzofuran-4-yl
2-(6-methoxynaphthalen-2-yl)propanoate (ABL-N),
which in preliminary studies showed exceptional anti-
proliferative activity against several human cancer cell
types. Here, we showed that ABL-N was more potent
than ABL in the ability to induce apoptosis, at a low
concentration, of human breast cancer cells and investi-
gated the therapeutic potential of the ABL-N and its
underlying mechanism of action.
Materials and methods
Preparation of ABL and ABL-N
Silica gel column chromatography was used to isolate
ABL from Inula britannica L grown in Shan-xi Province
in China. ABL-N was synthesized to improve efficacy
and pharmacologic characteristics by substitution at C-6
of ABL (Figure 1a). These compounds were character-
ized by nuclear magnetic resonance and mass spectro-
scopy. The purified ABL and ABL-N were dissolved in
ethanol at 1,000-fold final concentration and added to
cells in exponential growth. The effects of ABL and
ABL-N on our experiments were compared with the
same concentration of ethanol as vehicle.
Reagents
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro-
mide (MTT), DMSO, 4,6-diamidino-2-phenylindole
(DAPI), small interfering RNA (siRNA) specific for human
JNK mRNA and control siRNA were obtained from Sigma
C h e m i c a l s( S t .L o u i s ,M O ,U S A ) .L i p o f e c t A M I N E2 0 0 0 ,
Dulbecco’s modified Eagle’s medium (DMEM), penicillin,
and streptomycin were purchased from Invitrogen (Carls-
bad, CA, USA). The antibodies specific for Poly (ADP-
ribose) polymerase (PARP), c-Jun NH2-terminal kinase
(JNK), phospho-JNK, p38 MAP kinase (p38) and phos-
pho-p38 were obtained from Cell Signaling Technology
(Beverly, MA, USA). Antibodies against extracellular sig-
nal-regulated kinase (ERK), phospho-ERK, caspase-3, cas-
p a s e - 9 ,c - J u n ,p h o s p h o - c - J u n ,B c l - 2 ,B a x ,B a da n d
secondary antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Pan-caspase inhibitor (z-VAD-
fmk) was from Promega (Madison, WI, USA) and cas-
pase-3-specific inhibitor (z-DEVD-fmk) was obtained from
CalBiochem (San Diego, CA, USA). Unless otherwise indi-
cated, all other reagents used in this study were obtained
from Sigma Chemicals.
Cell lines and culture conditions
The human breast cancer cell lines (MCF-7, MDA-MB-
468 and MDA-MB-231), the human prostate carcinoma
cells (Du145 and PC-3), and the human colon carci-
noma cells (LoVo and HT-29) were from the American
Type Culture Collection. Normal human breast epithe-
lial cells (NBECs) were cultured and characterized as
described previously from reduction mammoplasty spe-
cimens [20,21]. Cells were grown in a 5% CO2 atmo-
sphere at 37°C in DMEM supplemented with 100 units/
ml penicillin, 100 μg/ml streptomycin, 1% nonessential
amino acids, and 10% fetal bovine serum (v/v). All treat-
ments were carried out on cells at 60 to 80% confluence.
Cell viability assay
Loss of cell viability was measured by the MTT assay.
Cells were seeded at 1 × 10
4 cells/well in 96-well plates
and allowed to grow in the growth medium for 24
hours. Cells were then treated with indicated concentra-
tions of ABL-N for various time periods. After drug
treatment, cells were incubated with 5 mg/ml MTT for
two hours, and subsequently solubilized in DMSO. The
absorbency at 570 nm was then measured using an
enzyme-linked immunosorbent assay (ELISA) reader.
The IC50 is the concentration agent that reduced the
cell viability by 50% under experimental conditions.
Experiments were repeated at least three times, and the
data were expressed as the means ± SE.
Nuclear staining assay
After treatment, the cells were harvested, washed with
phosphate-buffered saline (PBS), and fixed in 70% etha-
nol for 30 minutes. The fixed cells were placed on slides
and stained with 1 mg/ml DAPI for 15 minutes. Excess
dye was washed off with PBS. Nuclear morphology was
observed via a fluorescence microscope.
Cell cycle analysis
Cell cycle distribution was determined using flow cytome-
try analysis. Briefly, after treatment, cells were harvested
with 0.25% trypsin, washed in PBS and centrifuged. The
cells were fixed in ice-cold 75% ethanol for at least 30
minutes. Cells were washed and resuspended in PBS con-
taining 25 μg/ml RNase and 0.5% Triton X-100. Samples
were then incubated with 50 μg/ml propidium iodide (PI)
at 37°C for 30 minutes and analyzed in a flow cytometer
(Becton Dickinson, San Jose, CA, USA).
Cell apoptosis assay
Cell apoptosis was measured by ELISA and flow cyto-
metry, respectively. For ELISA, the cells seeded in 96-
well plates (1 × 10
4 cells/well) were treated with ABL-N
at 5, 10, 20 and 40 μM for 24 hours. Both floating and
adherent cells were collected and lysed. Each concentra-
tion of ABL-N was repeated five times. The induction of
apoptosis by the agent was evaluated with a Cell Death
Detection ELISA
Plus kit (Roche Diagnostics, Mannheim,
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Page 2 of 15Figure 1 Effect of ABL and ABL-N on cancer cell lines. (a) The chemical structures of ABL and ABL-N. (b) The differences of growth inhibition
activity between ABL and ABL-N in MDA-MB-231 cells. (c) Effects of ABL-N on the viability of various cancer cell lines. Cells were treated with
ABL-N for 24 hours and cell viability was determined by the MTT assay. The IC50 is the concentration of ABL-N that reduced the cell viability by
50% under the experimental conditions (n = 6). (d) Time- and dose-dependent inhibition of cell viability by ABL-N treatment in MDA-MB-231,
MCF-7, MDA-MB-468 and NBECs. Cells were treated with 5, 10, 20 or 40 μM ABL-N for 1, 3, 6, 12 and 24 hours and cell viability was assessed by
MTT assay (n = 6). Results represent the means ± SE from three independent experiments.
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Page 3 of 15Germany) according to the manufacturer’s instruction.
Photometric enzyme immunoassay was used to quanti-
tatively determine the formation of cytoplasmic his-
tone-associated DNA fragments in the form of
mononucleosomes and oligonucleosomes after apopto-
sis of the cells [22]. Measurements were made using
an ELISA reader at 405 nm and the results were calcu-
lated as the ratio of the absorbance of the ABL-N-trea-
ted cells/absorbance of untreated cells.
For flow cytometry, briefly, after treatment, cells were
collected and stained with Annexin V and PI staining
using annexin V-FITC apoptosis kit (BD Biosciences,
San Diego, CA, USA) according to the manufacturer’s
instruction. Early apoptotic (annexin V-positive and PI-
negative) cells were distinguished from late apoptotic
(annexin V and PI double-positive) or necrotic (PI-posi-
tive) cells by a flow cytometric analysis.
Western blot analysis
The cellular lysates were subjected to Western blot ana-
lysis as described previously [16,23]. Scanned images
were quantified using TotalLab TL120 software (Non-
linear Dynamics Ltd., Newscastle, United Kingdom).
JNK activity assay
Kinase activity of JNK was assayed with a nonradioactive
assay kit according to enclosed manufacturer’sp r o c e -
dures of Cell Signaling Technology. Briefly, after the cells
were treated, the lysates were prepared using a lysis buf-
fer (20 mM Tris (pH 7.5) containing 150 mM NaCl,
1m ME D T A ,1m ME G T A ,1 %T r i t o n ,2 . 5m Ms o d i u m
pyrophosphate, 1 mM b-glycerolphosphate, 1 mM phe-
nylmethylsulfonyl fluoride, 1 mM Na3VO4,a n d1μg/ml
leupeptin). JNK in approximately 250 μgo fp r o t e i n si n
each sample lysate was pulled down selectively by an
N-terminal c-Jun (residues 1 to 89) fusion protein that
were bound to glutathione sepharose beads at 4°C over-
night with gentle rocking. Thereafter beads were washed
twice with the lysis buffer and twice with kinase buffer
(25 mM Tris (pH 7.5) containing 5 mM b-glycerolpho-
sphate, 2 mM dithiothreitol, 0.1 mM sodium orthovana-
date, and 10 mM MgCl2). After the washings, pellets
were suspended in 50 μl of kinase buffer supplemented
with 200 μM ATP and incubated for 30 minutes at 30°C,
during which c-Jun fusion proteins were phosphorylated
by the activated JNK. JNK activity was analyzed by Wes-
tern blotting using a specific phospho-c-Jun (Ser63) anti-
body. To determine the direct effect of ABL-N on JNK
activity, in vitro cell-free kinase assays were also per-
formed using purified recombinant GST-JNK1 fusion
proteins (SignalChem, Richmond, British Columbia,
Canada). ABL-N and purified GST-JNK1 fusion proteins
were incubated for 12 hours and JNK activity assay was
also performed in a similar manner.
Measurement of caspase activities
Cells were treated with ABL-N, and the caspase-2, cas-
pase-3/7, caspase-6, caspase-8, and caspase-9 activities
in the cleared lysates were measured by using Caspase-
Glo 2, Caspase-Glo 3/7, Caspase-Glo 6, Caspase-Glo 8,
and Caspase-Glo 9 assays (Promega) according to the
manufacturer’s protocols. Luminescence was quantified
using an ELISA reader. Blank values were subtracted,
and increases in caspase activities were expressed as fold
increase and calculated based on activities measured
from untreated cells. Each sample was measured in
triplicates.
Transfection of siRNA
siRNAs specific for JNK (JNK siRNA) and control
siRNA were transiently transfected into cells using
transfection reagent (Lipofectamine 2000; Invitrogen)
according to the manufacturer’s protocol. JNK protein
levels were analyzed by Western blotting to confirm
adequate silencing of the genes at 48 hours.
Human breast tumor xenograft experiments
The animal study was performed via a protocol
approved by the governmental committee for animal
research. Female BALB/c nude mice (four- to five-weeks
old) were injected s.c. with MDA-MB-231 cells (6 ×
10
6) per mouse at both flanks. After six days, when
tumors reached a size of about 100 mm
3,m i c ew e r e
randomly grouped and treated by daily i.p. injection
with ABL-N at concentrations of 15 mg/kg body weight,
or vehicle (10% DMSO, 10% ethanol in water). Mice
were weighed at least twice a week to assess toxicity of
the treatment, and the tumor size was measured every
other day using calipers and their volumes were calcu-
lated according to a standard formula: width
2 ×l e n g t h /
2. Mice were sacrificed after 34 days of treatment when
control tumors reached about 1,600 mm
3.
Statistical analysis
Normal distribution of data was verified using the Sha-
piro-Wilk test. Statistical analysis was performed with
the two-tailed, unpaired Student’s t-test using SPSS 11.0
software. Results are given as means ± SE. A value of P
<0.05 was considered statistically significant.
Results
ABL-N reduces the viability of various carcinoma cell lines
The inhibitory effects of ABL and ABL-N on various
carcinoma cell lines were estimated using the MTT cel-
lular survival assay. MDA-MB-231 cells were treated for
24 hours with various concentrations of ABL and ABL-
N, and cell viability was expressed as percentage of
untreated cells. Figure 1b showed that ABL did not
affect cell viability at up to 40 μM; whereas this same
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indicated that ABL-N was dram a t i c a l l ym o r ee f f e c t i v e
than ABL in inhibiting the growth of cells.
Next, we examined the effects of ABL-N on the viabi-
lity of other human carcinoma cell lines. The results
showed that ABL-N treatment inhibited cell growth
with similar IC50 (approximately 12 to 20 μM) after a
24-hour treatment (Figure 1c). It indicated that ABL-N
was a broad-spectrum inhibitory agent of the human
carcinoma cells.
Furthermore, the sensitivity of three human breast
cancer cells to ABL-N was assessed. These cells were
chosen because they represent estrogen receptor (ER)-
negative (MDA-MB-231 and MDA-MB-468) and ER-
positive (MCF-7) cell lines. The data showed that the
inhibitory effects of ABL-N on cell viability occurred
very fast. Treating MDA-MB-231 cells for 12 hours with
20 and 40 μM ABL-N reduced cell viability by 51% and
62%, respectively (Figure 1d). Similar results were
observed in MDA-MB-468 and MCF-7 cells (Figure 1d).
These results showed that there was no relationship
between estrogen receptor status and cytotoxic effects of
ABL-N.
Moreover, we assessed whether ABL-N had any differ-
ential sensitivity to normal versus cancer cells. As
shown in Figure 1d, we found that the sensitivity of the
NBECs to ABL-N was much lower, with ABL-N only
having a significant effect on the viability (28% reduc-
tion, P< 0.05) of the NBECs following 24 hours of treat-
ment at the 40 μM dose, suggesting that ABL-N may
have potential selectivity toward tumor cells.
ABL-N arrests cells in G2/M phase of the cell cycle
Because ABL-N can effectively inhibit cell viability, we
reasoned that this effect might be attributable to its abil-
ity to interfere with the cell cycle. MDA-MB-231 cells
were incubated with 20 μM ABL-N for 6, 12 and 24
hours, and the cell cycle analysis was done by PI uptake.
Figure 2a shows that the ratio of cells in G2/M phase
and the cells with hypodiploid DNA contents (sub-G1)
were significantly accumulated over the treatment peri-
ods. In contrast, the cell cycle profile did not change
over a 24-hour period in cells treated with the vehicle
only (data not shown). Moreover, we also analyzed cell
cycle in MDA-MB-468 and MCF-7 cells and found the
G2/M arrest induced by ABL-N as well (data not
shown). Thus, it suggested that the inhibitory effect of
ABL-N on breast cancer cells might be, at least in part,
due to a G2/M arrest of the cell cycle.
ABL-N induces apoptosis in breast cancer cells
We next analyzed whether the ABL-N-induced cell via-
bility reduction in human breast cancer cells involved
apoptosis. MDA-MB-231 cells were treated with 20 μM
ABL-N and apoptosis was assayed by two different
methods. DAPI staining showed that the condensed and
fragmented nuclei increased with ABL-N treatment (Fig-
ure 2b). Nucleosome fragmentation (an indicator of
apoptosis) further determined by Cell Death Detection
ELISA
PLUS confirmed that cells treated for six hours
with 20 μM ABL-N underwent apoptosis, with the high-
est percentage of apoptotic cells seen at 24 hours (Fig-
ure 2c). In addition, an annexin V-binding assay showed
that ABL-N treatment induced apoptosis but not necro-
sis in MDA-MB-231 cells (Figure 2d). We also obtained
similar results when MDA-MB-468 and MCF-7 cells
were treated with ABL-N (data not shown).
ABL-N induces the activities of caspase in
breast cancer cells
To investigate the activation of caspases in ABL-N-
induced apoptosis, the proteolytic activation of caspase-
3 and caspase-9 was examined. As shown in Figure 3a,
ABL-N (20 μM) treatment resulted in a significant
increase in the active form of cleaved caspase-3 and
cleaved caspase-9 in MDA-MB-231 cells. The cleavage
products were detectable as early as six hours after
exposure of cells to ABL-N. Furthermore, caspase activ-
ities were measured with Caspase-Glo assays. As shown
in Figure 3b, treatment with ABL-N induced the activa-
tion of caspases-3/7, -8 and -9 in MDA-MB-231 cells.
Under similar conditions, ABL-N also stimulated cas-
pase-2 and -6 activities in a lesser extent. Similar results
were found in MDA-MB-468 cells (data not shown).
However, in ER-positive cell MCF-7, the activities of
caspase-3/7 and -9 were not affected by ABL-N,
although caspase-2 and -6 were activated to a level simi-
l a rt ot h a ts e e ni nM D A - M B - 2 3 1a n dM D A - M B - 4 6 8
cells (data not shown). However, we found that caspase-
8 activity is significantly higher in MCF-7 cells treated
with ABL-N, with the activity being increased by 2.8-
fold of the untreated cells at 24 hours. The activation of
caspases in MDA-MB-231 cells was further confirmed
by detecting the degradation of PARP, which is an endo-
genous substrate of activated caspase-3 and its cleavage
is considered a hallmark of apoptosis [24-26]. Treatment
of MDA-MB-231 cells with ABL-N resulted in cleavage
of PARP to an 85 kDa fragment (Figure 3c).
Caspase inhibitors attenuate the induction of
apoptosis by ABL-N
To define the role of caspase activation in ABL-N-
induced apoptosis, we treated MDA-MB-231 cells with
pan-caspase inhibitor z-VAD-fmk (50 μM) and caspase-
3-specific inhibitor (z-DEVD-fmk) (50 μM) before chal-
lenge with ABL-N (20 μM). z-VAD-fmk pretreatment
for one hour abrogated ABL-N-induced apoptosis as
measured by the nucleosome fragmentation and the
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Page 5 of 15Figure 2 Effect of ABL-N on cell cycle progression and apoptosis in breast cancer cells. After treatment with 20 μM ABL-N for indicated
times, MDA-MB-231 cells were harvested. (a) The percentage of cell cycle distribution for cells done in triplicate with similar results. (b) Nuclear
condensation was shown by DAPI-staining assay (magnification, ×100). (c) DNA fragmentation was evaluated using a Cell Death Detection
ELISA
Plus kit. The data are expressed as means ± SE of three separate experiments.*P< 0.05, **P< 0.01, as compared with the group without ABL-
N treatment. (d) The apoptotic status was determined by Annexin V/PI staining method. Percentages of negative (viable) cells, annexin V-positive
(early apoptotic) cells, PI-positive (necrotic) cells, or annexin V and PI double-positive (late apoptotic) cells were shown (mean of three
independent experiments) by a flow cytometric analysis.
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Page 6 of 15Figure 3 Induction of caspase activities by ABL-N. MDA-MB-231 cells were treated with 20 μMA B L - Nf o ri n d i c a t e dt i m e s .(a) Whole cell
protein lysates were prepared and subjected to Western blot analysis for detection of cleavage of caspase-3 and caspase-9. (b) Induction of
caspase activities by ABL-N in MDA-MB-231 cells. (c) Cleavage of PARP was induced by ABL-N. (d) Cells were pretreated with 50 μM of either z-
VAD-fmk or z-DEVD-fmk for one hour, followed by 20 μM ABL-N for 24 hours, and caspase-3 activity, DNA fragmentation and sub-G1 DNA
contents were determined. The data are expressed as means ± SE of three separate experiments. (e) Abrogation of PARP cleavage by caspase
inhibitors.
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Page 7 of 15appearance of sub-G1 cells (Figure 3d). Similar results
were observed in both MDA-MB-468 and MCF-7 cells
(data not shown). The caspase-3-specific inhibitor z-
DEVD-fmk also reduced ABL-N-induced apoptosis in
MDA-MB-231 cells (Figure 3d). Moreover, both of the
caspase inhibitors abolished caspase-3 activity in MDA-
MB-231 cells (Figure 3d). In addition, the cleavage of
PARP was attenuated by pretreatment of cells with z-
VAD-fmk or with z-DEVD-fmk in MDA-MB-231 cells
(Figure 3e). These results suggested that activation of a
caspase cascade was essential for ABL-N-induced apop-
tosis in breast cancer cells.
ABL-N modulates the expression of Bcl-2 family
proteins in breast cancer cells
Bcl-2 family of proteins, including Bcl-2 and Bcl-2-
related family members such as Bcl-xL, Bad and Bax,
plays an important role in the regulation of apoptosis
[27,28]. Thus, we evaluated the effects of ABL-N on the
expression of anti-apoptotic protein Bcl-2 and the pro-
apoptotic proteins Bax and Bad in breast cancer cells.
Figure 4a showed a marked increase in the level of Bax
and Bad, which started at six hours and peaked at 24
hours of treatment with ABL-N in MDA-MB-231 cells.
In contrast, reduced Bcl-2 protein appeared later at 12
h o u r s .T h e n ,t h er a t i oo fB a xa n dB c l - 2 ,w h i c hi st h e
determining factor for the induction of apoptosis [29],
was measured by a densitometric analysis of the bands.
As shown in Figure 4b, ABL-N treatment resulted in a
time-dependent increase in Bax/Bcl-2 ratio in MDA-
MB-231 cells that favors apoptosis.
ABL-N induces the activation of JNK and p38 signaling
in breast cancer cells
Activation of mitogen-activated protein (MAP) kinase is
involved in many aspects of the control of cellular pro-
liferation and apoptosis in response to a variety of extra-
cellular stimulus [30-32]. We therefore examined the
effects of ABL-N on the activation of several MAP
kinase pathways. The cell lysates from ABL-N-treated
MDA-MB-231 cells were subjected to Western blot ana-
lysis using antibodies that specifically recognize the
phosphorylated forms of JNK, p38 and ERK. As shown
in Figure 5a and 5b, ABL-N treatment induced activa-
tion of JNK and p38 in a time-dependent manner.
The activation of JNK by ABL-N was further confirmed
by the analysis of phosphorylation of its downstream sub-
strate c-Jun (Figure 5a). It showed that c-Jun was phos-
phorylated following ABL-N treatment, which occurred
over the same sustained period as JNK activation. How-
ever, no evident JNK and c-Jun phosphorylation could be
observed within three hours after ABL-N treatment.
Thus, JNK activation induced by ABL-N is a delayed and
sustained, but not an early and transient, process. To
gain further insight into the mechanism by which ABL-N
treatment affects JNK, we assayed JNK activity in ABL-
N-treated cells as well as the direct effect of ABL-N on
GST-JNK1 fusion proteins activity. As depicted in Figure
5c, JNK activity began to increase after treatment with 20
μM ABL-N for three hours and maximum activation was
achieved 12 hours after treatment. In addition, using
GST-JNK1 fusion proteins, we found that the JNK activ-
ity was unaffected by the presence of ABL-N (Figure 5d),
indicating ABL-N activated JNK indirectly by activating
signaling molecules located upstream in the JNK cas-
cades. On the contrary, ERK was revealed to be constitu-
tively activated in the cells and no significant change of
ERK expression and phosphorylation was observed after
ABL-N treatment (Figure 5e).
Suppression of JNK antagonized ABL-N-induced caspase-
3 activity and PARP cleavage
To determine the role of the activation of JNK and p38
in ABL-N-induced apoptosis, MDA-MB-231 cells were
treated with the JNK inhibitor SP600125 or the p38
inhibitor SB203580 and their effects on cell apoptosis
were examined. Additionally, we transfected MDA-MB-
231 cells with JNK siRNA or with a control siRNA for
48 hours. Transfection of JNK siRNA markedly reduced
t h ee x p r e s s i o no fJ N Kp r o t e i nc o m p a r e dw i t ht h a ti n
cells transfected with the control siRNA (Figure 6a). As
shown in Figure 6b, reduction of cell viability by ABL-N
was effectively abolished by SP600125, but SB203580
only had a slight effect on the decreased viability by
ABL-N. The cells transfected with the JNK siRNA also
blocked ABL-N-induced loss of cell viability. These
results suggested that the activation of JNK signaling is
responsible for the ABL-N-induced apoptosis. Similar
results were further confirmed by flow cytometic analy-
sis to determine the sub-G1 DNA contents (Figure 6c).
Similarly, JNK inhibition by its specific inhibitor or
siRNA could effectively antagonize ABL-N-induced cas-
pase-3 activity and PARP cleavage (Figure 6d). More-
over, the stimulatory effect of ABL-N on c-Jun
phosphorylation and JNK phosphorylation was not
altered by SB203580, but significantly reduced by
SP600125 (Figure 6e). These results suggested that acti-
vation of JNK, but not p38, was important for ABL-N-
induced apoptosis.
Furthermore, to address the possible role of caspase
cleavage in the activation of JNK pathway in ABL-N-
induced apoptosis, we observed the effect of caspase
inhibitors on JNK activation by ABL-N. The results
indicated that z-VAD-fmk (50 μM) or z-DEVD-fmk
(50 μM) pretreatment had no effect on c-Jun and JNK
activation induced by ABL-N (Figure 6f), further sug-
gesting that caspases were downstream targets of JNK
signaling in response to ABL-N in breast cancer cells.
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Page 8 of 15Figure 4 Effects of ABL-N on the expression of Bcl-2 family. (a) Treatment of ABL-N decreased the level of the anti-apoptotic protein Bcl-2,
but increased the expression of the pro-apoptotic proteins Bax and Bad in MDA-MB-231 cells. (b) Effect of ABL-N on the Bax/Bcl-2 ratio in MDA-
MB-231 cells. The data obtained from the Western blot analysis of Bax and Bcl-2 were used to evaluate the effect of ABL-N on the Bax/Bcl-2
ratio. The densitometric analysis of Bax and Bcl-2 bands was performed using TotalLab TL120 software, and the data (relative density normalized
to b-actin) were plotted as Bax/Bcl-2 ratio. Data are expressed as means ± SE of three separate experiments with similar results. *P< 0.05,
**P< 0.01, as compared with the group without ABL-N treatment.
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Page 9 of 15Figure 5 Time course of MAP kinase activation by ABL-N. MDA-MB-231 cells were treated with vehicle (0.5% ethanol) or 20 μMo fA B L - N
and harvested at the indicated times. (a) JNK; (b) p38; and (e) ERK activation was determined by Western blot analysis using antibodies that
recognize the phosphorylated form of the respective active MAP kinase. (c) JNK activity was determined by an in vitro kinase assay as described
in Materials and methods. Phosphorylation of c-Jun, which represents the intrinsic activity of JNK, was visualized by Western blotting. (d) ABL-N
(20 μM) and GST-JNK1 fusion proteins (1 μg) were incubated for 12 hours or cells were treated with ABL-N (20 μM) for 12 hours and lysates
were prepared, then JNK activity was measured as described above. Phosphorylation of c-Jun was visualized by Western blotting. The same blot
was stripped and reprobed with a c-Jun antibody to monitor equal loading of proteins. Data are representative of three independent
experiments.
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Page 10 of 15Figure 6 Role of JNK in ABL-N-induced apoptosis. MDA-MB-231 cells were incubated with ABL-N (20 μM) and either SB203580 (20 μM)
or SP600125 (30 μM), or a combination of both for 24 hours. (a) MDA-MB-231 cells were transfected with JNK siRNA (25 nM) or control siRNA
(25 nM) for 48 hours, and cell lysates were subjected to Western blot with antibodies to JNK. (b) ABL-N-induced cell death was abrogated by
inhibition of JNK using MTT assay. (c) Sub G1 DNA content was analyzed by flow cytometry. (d) Caspase-3 activity was determined by Caspase-
Glo assay and the cleavage of PARP was analyzed via Western blotting. Data are expressed as the means ± SE of three independent
experiments. (e) Effect of MAP kinase inhibitors on ABL-N-induced JNK activation. (f) Effect of caspase inhibitors on JNK activation. Cells
pretreated with or without z-VAD-fmk (50 μM) or z-DEVD-fmk (50 μM, one hour) were further incubated with vehicle or 20 μM ABL-N for
24 hours. Data are representative of three independent experiments.
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Page 11 of 15ABL-N inhibits the growth of human breast
cancer xenografts
Because ABL-N treatment showed the effective growth
inhibition in cultured breast cancer cells, we subsequently
carried out in vivo study using MDA-MB-231-derived can-
cer xenografts in nude mice. As shown in Figure 7, the i.p.
treatment with ABL-N (15 mg/kg) caused a significant
inhibition of tumor growth as early as 20 days after treat-
ment and persisted after 34 days. Furthermore, animals
showed no body weight loss, decreased activity, or anor-
exia (data not shown). This initial in vivo experiment sug-
gested that ABL-N might be an effective anticancer agent
at dosages that induced negligible toxic effects.
Discussion
Induction of apoptosis in malignant cells is a critical
property of chemopreventive agents. ABL, which has
been shown to be potently anti-tumorigenic, has pro-
apoptotic features in many carcinoma cell types [17-19].
We modified ABL to improve potency and pharmacolo-
gic characteristics, and obtained a highly active deriva-
tive ABL-N, which showed exceptional anti-proliferative
activity against several human cancer cell types. The dif-
ferences in biological activity of ABL and ABL-N could
be attributed to the difference in their structures (Figure
1a). The increased activity of ABL-N could be, most
likely, attributed to (S)-2-(6-methoxynaphthalen-2-yl)
propionyl- side chain of ABL-N, which is substituted
with hydroxyl group at C-6 in ABL. The purpose of this
study was to investigate the possible role of caspase acti-
vation and JNK signaling in ABL-N-induced apoptosis
in ER-positive and ER-negative breast cancer cells.
Apoptosis is governed by a complex network of anti-
apoptotic and pro-apoptotic effector molecules. Among
proteins implicated in control of apoptosis, members of
the Bcl-2 family have been demonstrated to be asso-
ciated with the mitochondrial membrane integrity [33].
They can activate or inhibit the release of downstream
factors such as cytochrome c which leads to the activa-
tion of caspase-3 and PARP in the execution of apopto-
sis [34]. Bax exerts pro-apoptotic activity by
translocation from the cytosol to the mitochondria,
where it induces cytochrome c release, while Bcl-2
exerts its anti-apoptotic activity, at least in part, by inhi-
biting the translocation of Bax to the mitochondria
[35,36]. Notably, the ratio ofp r o -a n da n t i - a p o p t o t i c
protein expression, such as Bax/Bcl-2, is critical for the
induction of apoptosis, and it decides the susceptibility
of cells to undergo apoptosis [29]. In the present study,
we showed that treatment of the MDA-MB-231 cells
with ABL-N resulted in significant decrease in the Bcl-2
protein and increase in the Bax protein, thus shifting
the Bax/Bcl-2 ratio in favor of apoptosis.
Caspases are known to act as key mediators of apop-
tosis and to contribute to the apoptotic morphology
through the cleavage of various cellular substrates. Cas-
pase-3 is an executioner member that can cleave specific
substrates such as PARP [37,38]. Here, the results that
caspase-3 activation was accompanied by PARP cleavage
in MDA-MB-231 and MDA-MB-468 ER-negative cells
indicated that caspase-3 might play a key role as an
important executioner in ABL-N-induced apoptosis in
these cell lines. It was further substantiated by the data
that caspase-3 inhibitor z-DEVD-fmk suppressed cell
Figure 7 The effect of ABL-N on the growth of MDA-MB-231 xenografts. Female nude mice bearing MDA-MB-231 tumor xenografts were
treated with ABL-N (15 mg/kg), or vehicle (10% DMSO, 10% ethanol in water), and tumors were measured with calipers on alternate days.
Points = mean tumor volume in each experimental group containing six mice; bars = SD; *, P < 0.05; **, P < 0.01, compared with vehicle
treated group.
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Page 12 of 15apoptosis induced by ABL-N. However, the absence of
caspase-3 activation in MCF-7 ER-positive cells [39]
raised the possibility that ABL-N might induce apoptosis
in MCF-7 cells through caspase-3-independent pathway.
It is demonstrated that curcumin and tributyrin could
induce apoptosis but independent of caspase-3 activa-
tion in MCF-7 cells [40,41]. Therefore, other caspases
might take part in ABL-N-induced apoptosis in MCF-7
cells. This was supported by our results that the pan-
caspase inhibitor z-VAD-fmk could abrogate ABL-N-
induced nucleosome fragmentation and the appearance
of sub-G1 cells. Our study further found that ABL-N
induced significant activation of caspase-8 in the breast
cancer cells, suggesting that ABL-N may activate the
death receptor pathway and induce the expression of
death receptors or death ligands such as tumor necrosis
factor-a and Fas ligand [42]. Thus, death receptor- or
mitochondria-mediated activation of the caspase may be
a potential mechanism underlying ABL-N-induced
apoptosis in breast cancer cells. Recently, it was
reported that another factor contributing to the activa-
tion of caspase is related to the inhibitors of apoptosis
proteins (IAPs), which have been revealed to inhibit
apoptosis due to their function as direct inhibitors of
caspases [43,44]. Many anticancer agents such as curcu-
min [45], epigallocatechin [46] and esculetin [47], have
been shown to interfere with IAPs and increase apopto-
sis rate. Consequently, we can hypothesize that ABL-N
possibly invokes similar pathways and further study is
necessary to investigate the precise mechanisms
responsible.
It is reported that the JNK pathway is very important in
cell apoptosis induced by various cytotoxic compounds
[30,46,47]. Studies reported here showed that ABL-N
induced activation of JNK beginning one hour after ABL-
N treatment and produced a sustained elevation for at
least 24 hours in MDA-MB-231 cells, which is much ear-
lier than the activation of caspase and the apoptosis.
Moreover, the JNK activation correlated with the
increased phosphorylated c-Jun, which appeared to play a
significant role in ABL-N-induced apoptosis and to cor-
relate with the activation of caspase. ABL-N could also
activate JNK in cells as monitored by JNK activity assay.
Several JNK isoforms, including JNK2 and JNK3, had
kinase activity in the absence of any activating upstream
kinase, which showed autophosphorylation activity
resulting in constitutive activation [48]. Therefore, we
use recombinant JNK1 proteins to determine the direct
effects of ABL-N on JNK. However, ABL-N did not acti-
vate GST-JNK1 fusion proteins in vitro kinase activity
assay, indicating ABL-N might act on JNK by the
upstream activators. Many studies have reported that
activation of JNK by its upstream kinases or molecules is
critical for its function. A number of factors, such as
MAP kinase kinase 4 (MKK4) [49], epidermal growth fac-
tor receptor (EGFR) [50], insulin growth factor receptor
(IGFR) [51] and spleen tyrosine kinase (SYK) [52], have
been implicated in the activation of JNK. Thus, further
studies will be required to determine how ABL-N acts
upstream of JNK. In addition, our data showed that
neither of the caspase inhibitors prevented ABL-N-
induced JNK activation, while JNK-specific inhibitor or
JNK siRNA, at least partially inhibited ABL-N-induced
apoptosis, indicating that JNK is upstream of caspases in
ABL-N-initiated apoptosis. Therefore, the results showed
that both the caspases and JNK pathway were necessary
to ABL-N-induced apoptosis in breast cancer cells
because interfering with either pathway could attenuate
apoptosis. Specifically, it was important to note that
interference with JNK using the specific inhibitor or
siRNA did not result in total abolition of ABL-N-induced
cell death, as shown by MTT and flow cytometry assays.
This may contribute to partial inhibition of JNK by
SP600125 or siRNA, since JNK inhibition led to signifi-
cant but not total reduction in phosphorylation of c-Jun.
Thus, it is likely that JNK-independent mechanisms may
participate in ABL-N-induced apoptosis.
Conclusions
In summary, our studies suggest for the first time that
ABL-N significantly induces apoptosis in breast cancer
cells. This induction is associated with the activation of
caspases and JNK signaling pathways. Moreover, ABL-N
treatment caused a significant inhibition of tumor
growth in vivo. Therefore, it is thought that ABL-N
might be a potential drug for use in breast cancer pre-
vention and intervention.
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